Clinical trials: Antiviral Agents
HIV Infections
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)
PRIMARY: To study the safety and tolerance of delavirdine mesylate ( U-90152 ) monotherapy. To compare the anti-HIV activity of three blood concentration levels of this agent with nucleoside analog monotherapy, either zidovudine…
- Trial name
- NCT00000810
- Testing
- Delavirdine mesylate, Zidovudine, Didanosine
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Hepatitis B
Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy
The literature suggests that there may be an association between hepatitis C and type 2 diabetes mellitus independent of the presence of cirrhosis, the likely mechanism for which is insulin resistance.
- Trial name
- NCT00188240
- Testing
- Pegasys; Copegus.
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Chronic Hepatitis C Virus Infection
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
The main objective of this study is to assess whether a recently-developed bioassay for the protein FGL2 can be used to predict the progression and/or response to treatment of Hepatitis C Virus disease in patients with chronic…
- Trial name
- NCT00606528
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
The primary objective of this study was to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in Egyptian adults with chronic genotype 4…
- Trial name
- NCT02487030
- Testing
- LDV/SOF, RBV
- Where
- 4 sites in Egypt
- Volunteers
- 255 people
- Sponsor
- Gilead Sciences
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04059198
- Testing
- Inarigivir soproxil, Tenofovir alafenamide fumarate (TAF)
- Where
- 2 sites in Hong Kong
- Volunteers
- 5 people
- Sponsor
- F-star Therapeutics, Inc.
Chronic Hepatitis C, Genotype 1
Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers
This is a non-randomized, open-label study examining the safety and efficacy of betaine in addition to standard anti-viral therapy in genotype 1 hepatitis C non-responders or relapsers to previous pegylated interferon plus…
- Conditions
- Chronic Hepatitis C, Genotype 1, Relapse
- Trial name
- NCT00882193
- Testing
- Betaine, Peginterferon alpha 2a, Ribavirin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Nebraska
Influenza
ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir
This pilot study is designed to demonstrate the feasibility of utilizing Emergency Departments (EDs) as a primary site for subject enrollment in clinical trials evaluating influenza therapeutics, and to provide pilot data for…
- Trial name
- NCT02609399
- Testing
- Oseltamivir, Peramivir
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Johns Hopkins University
Respiratory Failure, Hepatitis C
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent…
- Trial name
- NCT03625687
- Testing
- Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
HIV Infections
A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children
Monotherapy phase: To evaluate and compare the safety, tolerance, pharmacokinetics, and preliminary activity of nevirapine administered alone in mildly to moderately symptomatic HIV-infected children ages 2 months to less than 18…
- Trial name
- NCT00001111
- Testing
- Nevirapine, Zidovudine
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) single-tablet regimen…
- Trial name
- NCT01721109
- Testing
- EVG/COBI/FTC/TDF
- Where
- 18 sites in United States, South Africa and 1 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Efficacy of Extended Peginterferon Alpha 2a Treatment in HBeAg Positive Chronic Hepatitis B Patients
The most important method to slow down and stop the liver disease progression in patients with chronic hepatitis B is antiviral therapy, by which to achieve maintaining viral response during treatment or obtain sustained viral…
- Trial name
- NCT02387463
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Beijing Ditan Hospital
Herpes Simplex, HIV Infections
A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS
To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for refractory mucocutaneous herpes simplex virus disease in AIDS patients.
- Trial name
- NCT00002116
- Testing
- Cidofovir
- Where
- 9 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
HIV Infections
GW873140 to Treat HIV-1 Infected Adults
This study will determine which of four doses of GW873140 can safely be given to adults to lower the amount of virus (HIV-1) in the body. GW873140 is a new type of anti-HIV drug called a CCR5 receptor antagonist.
- Trial name
- NCT00076284
- Testing
- GW873140
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B Infection, Congenital Malformation
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission
Immunoprophylaxis with two hepatitis B vaccinations following the hepatitis B immune globulin (HBIg) and hepatitis B vaccine at birth is largely effective in protecting infants from hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia
- Trial name
- NCT03476083
- Testing
- Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
- Where
- 7 sites in China
- Volunteers
- 280 people
- Sponsor
- New Discovery LLC
Liver Disease
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
More than 1.5 millions individuals are infected with HCV in Italy. They are at risk to develop related morbidity and mortality from cirrhosis and hepatocellular carcinoma, unless the evolution of their disease is halted by…
- Trial name
- NCT01437969
- Testing
- genotyping and/or sequencing
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Veinous, Chemotherapy
A Retrospective, Observational, Multicenter Study to Evaluate the Safety and Performance of POLYSITE® and SEESITE® Implantable Ports
The purpose of this study is to evaluate performance and safety of POLYSITE® and SEESITE® implantable ports allowing repeated and prolonged access to the venous system for the administration of chemotherapy, antibiotics…
- Conditions
- Veinous, Chemotherapy, Antibiotics, Antiviral Drugs
- Trial name
- NCT05519761
- Testing
- Implantation of veinous access ports
- Where
- 3 sites in France
- Volunteers
- 250 people
- Sponsor
- Perouse Medical
Hepatitis, Hepatitis C
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
This is a randomized, multicenter, 2-part, open-label trial of the combination regimen of grazoprevir (GZR [MK-5172]; 100mg), uprifosbuvir (UPR [MK-3682]; 450 mg) and ruzasvir (RZR [MK-8408]; 60 mg) with and without Ribavirin…
- Conditions
- Hepatitis, Hepatitis C, Digestive System Diseases, Flaviviridae Infections
- Trial name
- NCT02613403
- Testing
- MK-3682B, Ribavirin
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E
To determine the time course of development of resistance to atevirdine mesylate ( U-87201E ) in patients with HIV isolates showing in vitro resistance to zidovudine ( AZT ).
- Trial name
- NCT00002094
- Testing
- Atevirdine mesylate
- Where
- United States
- Sponsor
- Pharmacia and Upjohn
Hepatitis C
Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy
The prevalence of HCV infection in Egypt is 14.7%. HCV is both a hepatotropic and a lymphotropic virus, it may exert a chronic stimulus on the immune system with both T and B lymphocyte alterations.
- Trial name
- NCT03226717
- Testing
- Antiviral agents
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
HIV-1-infection
Study of GS-1219 in Participants With HIV-1
This study is part of a master study. The goal of master protocol (GSUS-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1…
- Trial name
- NCT07115368
- Testing
- GS-1219, BVY, Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.